Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-inflammatory Effect of Fevipiprant in Asthma
NCT03989635Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of fevipiprant in asthma, sponsored by Novartis. Planned start Oct 2019; status: withdrawn.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03989635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989635.